Nkarta, Inc. Unrealized Gain (Loss) on Investments
Nkarta, Inc. (NKTX) reported Unrealized Gain (Loss) on Investments of -$295.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-10
- Nkarta, Inc. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$295.00K.
- Nkarta, Inc. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$537.00K.
- Nkarta, Inc. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was -$129.00K.
- Nkarta, Inc. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $174.00K, a 91.20% decline year-over-year.
- Nkarta, Inc. unrealized gain (loss) on investments for fiscal 2025 was -$267.00K, a 140.09% decline from fiscal 2024.
- Nkarta, Inc. unrealized gain (loss) on investments for fiscal 2024 was $666.00K, a 3.06% decline from fiscal 2023.
- Nkarta, Inc. unrealized gain (loss) on investments for fiscal 2023 was $687.00K.
- Nkarta, Inc. unrealized gain (loss) on investments for fiscal 2022 was -$529.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$295.00K 10-Q · filed 2026-08-10 | -$832.00K 10-Q · filed 2026-08-10 | -$961.00K derived: sum of 3 quarters · filed 2026-08-10 | -$787.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$537.00K 10-Q · filed 2026-05-12 | -$666.00K derived: sum of 2 quarters · filed 2026-05-12 | -$492.00K derived: sum of 3 quarters · filed 2026-05-12 | -$782.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $45.00K derived: sum of 2 quarters · filed 2026-03-25 | -$245.00K derived: sum of 3 quarters · filed 2026-08-10 | -$267.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | $174.00K 10-Q · filed 2025-11-10 | -$116.00K derived: sum of 2 quarters · filed 2026-08-10 | -$138.00K 10-Q · filed 2025-11-10 | -$1.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$290.00K 10-Q · filed 2026-08-10 | -$312.00K 10-Q · filed 2026-08-10 | -$1.35M derived: sum of 3 quarters · filed 2026-08-10 | $625.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$22.00K 10-Q · filed 2026-05-12 | -$1.06M derived: sum of 2 quarters · filed 2026-05-12 | $915.00K derived: sum of 3 quarters · filed 2026-05-12 | $779.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $937.00K derived: sum of 2 quarters · filed 2026-03-25 | $801.00K derived: sum of 3 quarters · filed 2026-03-25 | $666.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $1.98M 10-Q · filed 2025-11-10 | $1.84M derived: sum of 2 quarters · filed 2025-11-10 | $1.71M 10-Q · filed 2025-11-10 | $2.12M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$136.00K 10-Q · filed 2025-08-12 | -$271.00K 10-Q · filed 2025-08-12 | $146.00K derived: sum of 3 quarters · filed 2025-08-12 | $338.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$135.00K 10-Q · filed 2025-05-14 | $282.00K derived: sum of 2 quarters · filed 2025-05-14 | $474.00K derived: sum of 3 quarters · filed 2025-05-14 | $47.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $417.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $609.00K derived: sum of 2 quarters · filed 2025-03-26 | $182.00K derived: sum of 3 quarters · filed 2025-03-26 | $687.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $192.00K 10-Q · filed 2024-11-07 | -$235.00K derived: sum of 2 quarters · filed 2024-11-07 | $270.00K 10-Q · filed 2024-11-07 | $912.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$427.00K 10-Q · filed 2024-08-13 | $78.00K 10-Q · filed 2024-08-13 | $720.00K derived: sum of 3 quarters · filed 2024-08-13 | $330.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $505.00K 10-Q · filed 2024-05-09 | $1.15M derived: sum of 2 quarters · filed 2024-05-09 | $757.00K derived: sum of 3 quarters · filed 2024-05-09 | $432.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $642.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $252.00K derived: sum of 2 quarters · filed 2024-03-21 | -$73.00K derived: sum of 3 quarters · filed 2024-03-21 | -$529.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | -$390.00K 10-Q · filed 2023-11-09 | -$715.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.17M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$325.00K 10-Q · filed 2023-08-10 | -$781.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$456.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |